et al. Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis. Oncotarget 9, 24801–24820 (2018). Article PubMed PubMed Central Google Scholar Muntasell, A. et al. NK cell infiltr
In this Review, we highlight the variety of ways in which diverse NK cell products and their auxiliary therapeutics are being leveraged to target human cancers. We also identify future avenues for NK cell therapy research. Key points Natural killer (NK) cell-based therapies are emerging as ...
[15] The unique biological features of NK cells make them an more attractive source for genetically modified immune cell-based immunotherapy. First, compared to the CAR-T cells, superior safety of the unmodified NK cells and more recently CAR-NK cell immunotherapy has been shown in several ...
5 晚期非小细胞肺癌患者采用改良CAR-NK治疗后，肿瘤显著缩小！一项于2022年5月3日发表于《Cell Transpla...
Notable, recent studies in adoptive NK cell therapy have shown promise in rejuvenating immunosenescence, eliminating SNCs, and alleviating SASPs. This progress provides the proof-concept of adoptive NK cell therapy for senotherapy and holds promise as an emerging revolution in longevity therapeutics....
First comprehensive summary of the recent advances in the use of nanomaterials for enhancing NK cell-based tumor immunotherapy. • The mechanisms of NK cell activation and inhibition for immunotherapy. • Rational design and fabrication of nanomaterials to elaborately enhance NK cell-based tumor immu...
他正与总部位于圣地亚哥的Fate Therapeutics公司的科学家们合作,以推进临床试验的开展。未来,他们将继续在乳腺癌、脑瘤等实体瘤以及白血病等血液癌中验证来源于iPSCs的CAR-NK细胞的可行性。责编:艾曼参考资料:1)CAR-Timmunotherapies may have a new player原标题:比CAR-T更安全!CAR-NK疗法初显成效 | Cell子刊 送...
2. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. doi: 10.1126/science.1251102. 3. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. doi: 10.1126/science.aaa1348. ...
About Fate Therapeutics’ iPSC Product PlatformThe Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that are designed to be administered with multiple doses to deliver more effective pha...
“Expansion and Activation of Natural Killer Cells for Cancer Immunotherapy.” Korean J. Lab. Med. 29.2(2009):89-96. Decot et al. “Natural-Killer Cell Amplification for Adoptive Leukemia Relapse Immunotherapy: Comparison of Three Cytokines, IL-2, IL-15, or IL-7 and Impact on NKG2D, ...